Details About Generic Salt ::  Vinorelb

Main Medicine Class::    

(vih-NORE-ell-bean)

Navelbine

Solution for Injection

10 mg/mL

Class: Vinca alkaloid

 Indications Unresectable, advanced non-small cell lung cancer.

Breast cancer, cisplatin-resistant ovarian cancer, Hodgkin’s lymphoma.

 Contraindications Pretreatment granulocyte counts < 1000 cells/mm³.

 Route/Dosage

Unresectable, Advanced Non-Small Cell Lung Cancer

ADULTS: IV 30 mg/m² once weekly until either disease progression or dose-limiting toxicity occur.

Dosage Adjustment for Hematologic Toxicity

Granulocyte counts should be ³ 1000 cells/mm³ prior to the administration of vinorelbine. Base dosage adjustments on granulocyte counts. See manufacturer’s recommendations.

Dosage Adjustment in Hepatic Dysfunction

ADULTS: IV Reduce dose 50% if total bilirubin is 2.1 to 3 mg/dL. Reduce dose 25% if total bilirubin is > 3 mg/dL.

Interactions

Cisplatin

Incidence of granulocytopenia increases when vinorelbine is used in combination with cisplatin.

Cytochrome P450 3A enzyme inhibitors (eg ketoconazole, itraconazole, macrolides)

May increase vinorelbine serum levels and toxicity.

Mitomycin

Acute pulmonary reactions were noted when vinca alkaloids were given with mitomycin.

Paclitaxel

Monitor for signs and symptoms of neuropathy with concomitant use of vinorelbine and paclitaxel.

Radiation

Radiation recall reactions may occur.

Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Chest pain. CNS: Fatigue; mild to moderate peripheral neuropathy. DERMATOLOGIC: Mild alopecia; rash and injection site reactions; pain at injection site. GI: Transient elevations in LFTs; constipation; paralytic ileus; mild stomatitis; anorexia; diarrhea. HEMATOLOGIC: Dose-limiting granulocytopenia occurs with a nadir of 7 to 10 days. HYPERSENSITIVITY: Anaphylaxis; angioedema; pruritus. MUSCULOSKELETAL: Jaw pain; myalgia; arthralgia. RESPIRATORY: Dyspnea.

 Precautions

Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy in children have not been established. Interstitial pulmonary changes: Cases of interstitial pulmonary changes and ARDS, most of which were fatal, occurred in patients. GI: May cause severe constipation, paralytic ileus, intestinal obstruction, necrosis, and perforation. Granulocytopenia: Granulocytopenia is dose-limiting. Do not administer to patients with granulocyte counts < 1000 cells/mm³. Hepatic function impairment: Administer with caution to patients with hepatic insufficiency. IV use only: Intrathecal use may result in death. Extravasation: Extravasation can cause severe local necrosis.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• Refrigerate but do not freeze. Protect from light. Unopened vials may be stored at room temperature £ 25°C (77°F) for £ 72 hr. Diluted solutions may be stored at room temperature or under refrigeration for £ 24 hr in polypropylene syringes or PVC bags. Solutions are preservative-free and should be discarded within 24 hr of preparation.
• Vinorelbine must be further diluted prior to administration.
• Administer by IV infusion
• Infuse IV over 6 to 10 min into the side port of a freely flowing IV line closest to the IV bag. Follow injection with ³ 75 to 125 mL 5% Dextrose or 0.9% Sodium Chloride.

 Assessment/Interventions

• Monitor CBC with differential and serum bilirubin concentrations at baseline and prior to each dose.
• Use with caution in patients receiving other bone marrow suppressants, with prior radiation therapy, or with a history of neuropathy or pulmonary dysfunction.
• Patients who develop bronchospasm during infusions may be treated with supplemental oxygen, bronchodilators, or corticosteroids.
• Monitor patients developing severe granulocytopenia for evidence of infection or fever.
• Monitor patients with a history of or with preexisting neuropathy, for new or worsening signs and symptoms of neuropathy.
• Promptly evaluate patients with alterations in their baseline pulmonary symptoms or with new onset of dyspnea, cough, hypoxia, or other symptoms.

OVERDOSAGE: SIGNS & SYMPTOMS   Paralytic ileus, stomatitis, esophagitis, bone marrow aplasia, sepsis, paresis

 Patient/Family Education

• Advise patients to report fever or chills immediately.
• Advise women of childbearing potential to avoid pregnancy during treatment.
• Advise patients to contact the health care provider if experiencing increased shortness of breath, cough, or other new pulmonary symptoms, or if experiencing symptoms of abdominal pain or constipation.

Medicscientist Drug Facts

 

Drugs Class ::

(vih-NORE-ell-bean)

Navelbine

Solution for Injection

10 mg/mL

Class: Vinca alkaloid

Indications for Drugs ::

 Indications Unresectable, advanced non-small cell lung cancer.

Breast cancer, cisplatin-resistant ovarian cancer, Hodgkin’s lymphoma.

Drug Dose ::

 Route/Dosage

Unresectable, Advanced Non-Small Cell Lung Cancer

ADULTS: IV 30 mg/m² once weekly until either disease progression or dose-limiting toxicity occur.

Dosage Adjustment for Hematologic Toxicity

Granulocyte counts should be ³ 1000 cells/mm³ prior to the administration of vinorelbine. Base dosage adjustments on granulocyte counts. See manufacturer’s recommendations.

Dosage Adjustment in Hepatic Dysfunction

ADULTS: IV Reduce dose 50% if total bilirubin is 2.1 to 3 mg/dL. Reduce dose 25% if total bilirubin is > 3 mg/dL.

Contraindication ::

 Contraindications Pretreatment granulocyte counts < 1000 cells/mm³.

Drug Precautions ::

 Precautions

Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy in children have not been established. Interstitial pulmonary changes: Cases of interstitial pulmonary changes and ARDS, most of which were fatal, occurred in patients. GI: May cause severe constipation, paralytic ileus, intestinal obstruction, necrosis, and perforation. Granulocytopenia: Granulocytopenia is dose-limiting. Do not administer to patients with granulocyte counts < 1000 cells/mm³. Hepatic function impairment: Administer with caution to patients with hepatic insufficiency. IV use only: Intrathecal use may result in death. Extravasation: Extravasation can cause severe local necrosis.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Chest pain. CNS: Fatigue; mild to moderate peripheral neuropathy. DERMATOLOGIC: Mild alopecia; rash and injection site reactions; pain at injection site. GI: Transient elevations in LFTs; constipation; paralytic ileus; mild stomatitis; anorexia; diarrhea. HEMATOLOGIC: Dose-limiting granulocytopenia occurs with a nadir of 7 to 10 days. HYPERSENSITIVITY: Anaphylaxis; angioedema; pruritus. MUSCULOSKELETAL: Jaw pain; myalgia; arthralgia. RESPIRATORY: Dyspnea.

Drug Mode of Action ::  

(vih-NORE-ell-bean)

Navelbine

Solution for Injection

10 mg/mL

Class: Vinca alkaloid

Drug Interactions ::

Interactions

Cisplatin

Incidence of granulocytopenia increases when vinorelbine is used in combination with cisplatin.

Cytochrome P450 3A enzyme inhibitors (eg ketoconazole, itraconazole, macrolides)

May increase vinorelbine serum levels and toxicity.

Mitomycin

Acute pulmonary reactions were noted when vinca alkaloids were given with mitomycin.

Paclitaxel

Monitor for signs and symptoms of neuropathy with concomitant use of vinorelbine and paclitaxel.

Radiation

Radiation recall reactions may occur.

Drug Assesment ::

 Assessment/Interventions

• Monitor CBC with differential and serum bilirubin concentrations at baseline and prior to each dose.
• Use with caution in patients receiving other bone marrow suppressants, with prior radiation therapy, or with a history of neuropathy or pulmonary dysfunction.
• Patients who develop bronchospasm during infusions may be treated with supplemental oxygen, bronchodilators, or corticosteroids.
• Monitor patients developing severe granulocytopenia for evidence of infection or fever.
• Monitor patients with a history of or with preexisting neuropathy, for new or worsening signs and symptoms of neuropathy.
• Promptly evaluate patients with alterations in their baseline pulmonary symptoms or with new onset of dyspnea, cough, hypoxia, or other symptoms.

OVERDOSAGE: SIGNS & SYMPTOMS   Paralytic ileus, stomatitis, esophagitis, bone marrow aplasia, sepsis, paresis

Drug Storage/Management ::

 Administration/Storage

• Refrigerate but do not freeze. Protect from light. Unopened vials may be stored at room temperature £ 25°C (77°F) for £ 72 hr. Diluted solutions may be stored at room temperature or under refrigeration for £ 24 hr in polypropylene syringes or PVC bags. Solutions are preservative-free and should be discarded within 24 hr of preparation.
• Vinorelbine must be further diluted prior to administration.
• Administer by IV infusion
• Infuse IV over 6 to 10 min into the side port of a freely flowing IV line closest to the IV bag. Follow injection with ³ 75 to 125 mL 5% Dextrose or 0.9% Sodium Chloride.

Drug Notes ::

 Patient/Family Education

• Advise patients to report fever or chills immediately.
• Advise women of childbearing potential to avoid pregnancy during treatment.
• Advise patients to contact the health care provider if experiencing increased shortness of breath, cough, or other new pulmonary symptoms, or if experiencing symptoms of abdominal pain or constipation.

Medicscientist Drug Facts

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.